Roche/Trimeris Fuzeon Discontinuation Rate Is One Factor In Poor Sales
This article was originally published in The Pink Sheet Daily
Sales of the HIV agent remain disappointing at $35.9 mil. worldwide for 2003. Roche says it remains convinced Fuzeon can reach peak targets – just not as quickly as it hoped.
You may also be interested in...
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.